MyD88 signaling controls autoimmune myocarditis induction.

Area of Science:

• Immunology
• Cardiovascular Research
• Autoimmunity

Background:

• Experimental autoimmune myocarditis (EAM) is a CD4+ T-cell model for postviral cardiomyopathy.
• Myeloid differentiation primary response 88 (MyD88) is essential for Toll-like receptor and IL-1 receptor signaling.
• The specific function of MyD88 in myocarditis pathogenesis remained unclear.

Purpose of the Study:

• To investigate the role of MyD88 in the development of experimental autoimmune myocarditis.
• To determine the cellular source of MyD88 signaling critical for disease induction.

Main Methods:

• Utilized MyD88-deficient (MyD88(-/-)) and wild-type (MyD88(+/+)) mice.
• Immunized mice with alpha-myosin heavy chain peptide (MyHC-alpha) to induce EAM.
• Assessed CD4+ T cell expansion, dendritic cell (DC) function, and cytokine production.

Main Results:

• MyD88(-/-) mice were protected from EAM, showing reduced heart-specific CD4+ T cell expansion.
• MyD88(-/-) dendritic cells exhibited impaired T cell priming capacity due to defective tumor necrosis factor-alpha release.
• Restoration of MyD88 signaling in DCs fully reinstated T cell expansion and myocarditis in MyD88(-/-) mice.

Conclusions:

• MyD88 signaling within antigen-presenting cells in peripheral compartments is essential for autoimmune myocarditis development.
• Targeting MyD88 signaling in these cells offers a potential strategy for preventing heart-specific autoimmunity and cardiomyopathy.